{
  "ticker": "TLX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02976845",
  "id": "02976845",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250805",
  "time": "0830",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250805/pdf/06mjpdy4k87wk7.pdf",
  "summary": "### **Material Information Summary**  \n\n- **Reporting Currency Change**: Telix switched from AUD to USD as its reporting currency effective **1 January 2025**, aligning with its predominantly USD-denominated revenue and costs.  \n- **H1 2025 OPEX Guidance**: Operating expenditure (excluding R&D) expected to be **~36% of revenue** (~$86.3M based on H1 2024 revenue). Reflects expanded operations post-RLS Radiopharmacies acquisition (completed **27 January 2025**).  \n- **Financial Highlights (Recast, Unaudited)**:  \n  - **H1 2024**: Revenue **$239.6M** (up 61% YoY), gross margin **66%**, operating profit **$27.7M**.  \n  - **FY 2024**: Revenue **$516.6M**, gross margin **65%**, operating profit **$55.2M**.  \n  - **Cash**: FY 2024 closing balance **$440.0M** (vs. $84.3M in FY 2023), bolstered by **$416.8M net financing cash inflows** (incl. convertible bonds).  \n- **Upcoming Catalyst**: Interim results for H1 2025 to be released on **21 August 2025**.  \n\n*No capital raising, trading halt, or exceptional operational updates identified.*",
  "usage": {
    "prompt_tokens": 7136,
    "completion_tokens": 290,
    "total_tokens": 7426,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-04T22:45:10.743267"
}